Jonathan H. Dinsmore

Health Technology

Consumer Services

Profile

Jonathan H.
Dinsmore is Senior Vice President-Regulatory and Clinical of Advanced Cell Technology, Inc. Previously, he was President, Chief Scientific Officer and a Director of Mytogen, Inc. Dr. Dinsmore worked for Diacrin and GenVec.
He received a BS degree in Biology from Boston College in 1983 and a PhD degree in Biology from Dartmouth College in 1988.

Former positions of Jonathan H. Dinsmore

Companies	Position	End
OCATA THERAPEUTICS INC	General Counsel	-
Mytogen, Inc. Mytogen, Inc. BiotechnologyHealth Technology Mytogen, Inc. provides healthcare services. It focuses on using myoblasts, stem cells that form muscle, to treat patients with cardiac indications such as congestive heart failure, a progressive deterioration of the heart muscle. The company was founded in 1990 and is headquartered in Los Angeles, CA.	President	-

See the detail of Jonathan H. Dinsmore's experience

Training of Jonathan H. Dinsmore

Boston College	Undergraduate Degree
Dartmouth College	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jonathan H. Dinsmore's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Mytogen, Inc. Mytogen, Inc. BiotechnologyHealth Technology Mytogen, Inc. provides healthcare services. It focuses on using myoblasts, stem cells that form muscle, to treat patients with cardiac indications such as congestive heart failure, a progressive deterioration of the heart muscle. The company was founded in 1990 and is headquartered in Los Angeles, CA.	Health Technology
Astellas Institute for Regenerative Medicine Astellas Institute for Regenerative Medicine Pharmaceuticals: MajorHealth Technology Astellas Institute for Regenerative Medicine engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA.	Health Technology